Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ERBB3 over exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches | HER inhibitor (Pan) HER2 (ERBB2) Antibody HER2 (ERBB2) Vaccine HER2 Inhibitor HER3 (ERBB3) Antibody HER3 Inhibitor |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04965766 | Phase II | Patritumab deruxtecan | Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS BREAST) | Recruiting | FRA | 0 |
| NCT05057013 | Phase Ib/II | HMBD-001 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | Active, not recruiting | GBR | 0 |